These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35582980)

  • 1. Haematological changes and adverse events associated with BNT162b2 mRNA COVID-19 vaccine in patients receiving clozapine-Findings from an audit.
    Lim S; Liew E; Leo A; Ng BT; Lee J
    Acta Psychiatr Scand; 2022 Aug; 146(2):179-181. PubMed ID: 35582980
    [No Abstract]   [Full Text] [Related]  

  • 2. Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
    Auster O; Finkel U; Dagan N; Barda N; Laufer A; Balicer RD; Ben-Shachar S
    JAMA Netw Open; 2022 Apr; 5(4):e227657. PubMed ID: 35435973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine.
    Juddoo V; Juddoo S; Mégarbane B
    Vaccine; 2022 Apr; 40(19):2650-2651. PubMed ID: 35365342
    [No Abstract]   [Full Text] [Related]  

  • 4. Post BNT162b2 mRNA COVID-19 vaccination Henoch-Schӧnlein Pupura.
    Wang SSY
    Postgrad Med J; 2022 Dec; 98(1166):900-901. PubMed ID: 35022253
    [No Abstract]   [Full Text] [Related]  

  • 5. Leukocytoclastic vasculitis in possible relation to the BNT162b2 mRNA COVID-19 vaccine.
    Carrillo-Garcia P; Sánchez-Osorio L; Gómez-Pavón J
    J Am Geriatr Soc; 2022 Apr; 70(4):971-973. PubMed ID: 35099065
    [No Abstract]   [Full Text] [Related]  

  • 6. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: An observational study.
    Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
    Br J Haematol; 2022 Jun; 197(6):709-713. PubMed ID: 35262920
    [No Abstract]   [Full Text] [Related]  

  • 7. Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine.
    Felices-Farias JM; Martínez-Martínez JF; Guzmán-Aroca F
    Med Clin (Barc); 2022 Apr; 158(7):343-344. PubMed ID: 34229883
    [No Abstract]   [Full Text] [Related]  

  • 8. Psoriatic arthritis flare-up after a second dose of BNT162b2 COVID-19 mRNA vaccine.
    Watabe D; Tsunoda K; Amano H
    Eur J Dermatol; 2022 May; 32(3):420-421. PubMed ID: 36065550
    [No Abstract]   [Full Text] [Related]  

  • 9. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre.
    Koumaki D; Krueger-Krasagakis SE; Papadakis M; Katoulis AC; Gkiaouraki I; Zografaki K; Mylonakis D; Krasagakis K
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e411-e415. PubMed ID: 35075691
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on: COVID-19 vaccine (mRNA BNT162b2) and COVID-19 infection-induced thrombotic thrombocytopenic purpura in adolescents.
    Sookaromdee P; Wiwanitkit V
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29749. PubMed ID: 35484992
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
    BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient.
    Jakimovski D; Weinstock-Guttman B
    Acta Neurol Belg; 2022 Apr; 122(2):565-566. PubMed ID: 34529258
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 14. Why two doses of the BNT162b2 mRNA COVID-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA COVID-19 and other vaccines.
    LA Vecchia C; Centanni S; Gerli AG
    Panminerva Med; 2022 Mar; 64(1):131-132. PubMed ID: 33480519
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases.
    Cheng FWT; Fan M; Wong CKH; Chui CSL; Lai FTT; Li X; Wan EYF; Tang SCW; Chan EWY; Wong ICK
    Kidney Int; 2022 Oct; 102(4):922-925. PubMed ID: 35964798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
    Novembre E; Tosca M; Caffarelli C; Calvani M; Cardinale F; Castagnoli R; Chiappini E; Cravidi C; Del Giudice MM; Duse M; Licari A; Manti S; Martelli A; Ricci G; Pingitore G; Marseglia GL
    Ital J Pediatr; 2022 May; 48(1):76. PubMed ID: 35578294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of Myocarditis Presenting With a Hyperechoic Nodule After the First Dose of COVID-19 mRNA Vaccine.
    Park S; You J
    J Korean Med Sci; 2022 Apr; 37(16):e131. PubMed ID: 35470603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo posttransplant membranous nephropathy following BNT162b2 mRNA COVID-19 vaccine in a kidney transplant recipient.
    Chavarot N; Padden M; Amrouche L; Malard S; Scemla A; Sberro-Soussan R; Léon J; Legendre C; Duong JP; Zuber J; Anglicheau D; Rabant M; Isnard P
    Am J Transplant; 2022 Dec; 22(12):3188-3189. PubMed ID: 35959598
    [No Abstract]   [Full Text] [Related]  

  • 20. De novo PLA2R positive membranous nephropathy following BNT162b2 mRNA COVID-19 vaccine.
    Paxton L; McMahon L; Wong L
    Intern Med J; 2022 Dec; 52(12):2191-2192. PubMed ID: 36000353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.